Theresa A. Proia - Concepedia

Author

Theresa A. Proia

AstraZeneca (United States)

Also Known As

Proia, Theresa, Skibinski, Adam, T. Proia, T.A. Proia, Theresa A Proia, Theresa A. Proia, Theresa Proia

157

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (United Kingdom)AstraZeneca (Brazil)AstraZeneca (Singapore)AstraZeneca (South Korea)

About

Theresa A. Proia is an author at AstraZeneca (United States) specializing in medicine, cell biology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	458
2	Cell Biology	4	4	458
3	Cancer Genetics	2	2	411
4	Cancer Cell Biology	1	1	11
5	Cancer Therapeutics	1	1	36

Theresa A. Proia

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell Fate Theresa A. Proia, Patricia J. Keller, Piyush B. Gupta, Cell stem cell Lineage PlasticityBreast OncologyDevelopmental BiologyTumor HeterogeneityGenetics	2011	400
Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress Yuxiong Feng, Ethan S. Sokol, Catherine Del Vecchio Fitz, Cancer Discovery	2014	322
Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation Sarah Phillips, Aleix Prat, Maja Sedic, Stem Cell Reports	2014	115
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies Bernard Barlaam, Robert Casella, Justin Cidado, Journal of Medicinal Chemistry	2020	98
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Nabendu Pore, Song Wu, Nathan Standifer, Cancer Discovery	2021	77
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Matthew J. Sale, Emma Minihane, Noel R. Monks, Nature Communications	2019	72
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 Theresa A. Proia, Maneesh Singh, Richard Woessner, Clinical Cancer Research	2020	50
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors Anna D. Staniszewska, Joshua Armenia, Matthew King, OncoImmunology	2022	46
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide Ayman Oweida, Adam C. Mueller, Miles Piper, Cancer Immunology Immunotherapy Pancreatic CancerStat3 Anti-sense OligonucleotideMedicineMyeloid-derived Suppressor CellsPancreatic Ductal Adenocarcinoma	2020	36
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas Scott Boiko, Theresa A. Proia, Maryann San Martin, Blood	2020	29

Page 1